Recombinant
RabMAb

Anti-HLA-DPB1 antibody [EPR11226] (ab157210)

Overview

  • Product name
    Anti-HLA-DPB1 antibody [EPR11226]
    See all HLA-DPB1 primary antibodies
  • Description
    Rabbit monoclonal [EPR11226] to HLA-DPB1
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-P, ICC/IF, IPmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human HLA-DPB1. The exact sequence is proprietary.

  • Positive control
    • Human fetal thymus and Human tonsil lysates; Human tonsil tissue; Jurkat cells; Immunoprecipitation pellet from fetal thymus lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
  • Storage buffer
    Preservative: 0.01% Sodium azide
    Constituents: 40% Glycerol, 0.05% BSA, 59% PBS
  • Concentration information loading...
  • Purity
    Protein A purified
  • Clonality
    Monoclonal
  • Clone number
    EPR11226
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab157210 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/10000 - 1/50000. Predicted molecular weight: 29 kDa.
IHC-P 1/2500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

For unpurified, use 1/100 - 1/250.

ICC/IF 1/50 - 1/250.
IP 1/10 - 1/100.
  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function
      Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
    • Sequence similarities
      Belongs to the MHC class II family.
      Contains 1 Ig-like C1-type (immunoglobulin-like) domain.
    • Cellular localization
      Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus, trans-Golgi network membrane. Endosome membrane. Lysosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
    • Information by UniProt
    • Database links
    • Alternative names
      • beta1 domain MHC class II HLA DPB antibody
      • class II histocompatibility antigen, DP(W4) beta chain antibody
      • class II HLA beta chain antibody
      • DP beta 1 chain antibody
      • DP(W4) beta chain antibody
      • DPB1 antibody
      • DPB1_HUMAN antibody
      • HLA class II histocompatibility antigen antibody
      • HLA class II histocompatibility antigen, DP beta 1 chain antibody
      • HLA class II histocompatibility antigen, DP(W4) beta chain antibody
      • HLA DP14-beta chain antibody
      • HLA-DP antibody
      • HLA-DP histocompatibility type, beta-1 subunit antibody
      • HLA-DP1B antibody
      • HLA-DPB antibody
      • HLA-DPB1 antibody
      • major histocompatibility complex class II antigen beta chain antibody
      • major histocompatibility complex, class II, DP beta 1 antibody
      • MHC class II antigen beta chain antibody
      • MHC class II antigen DP beta 1 chain antibody
      • MHC class II antigen DPB1 antibody
      • MHC class II antigen DPbeta1 antibody
      • MHC class II HLA-DP-beta-1 antibody
      • MHC class II HLA-DRB1 antibody
      • MHC HLA DPB1 antibody
      see all

    Images

    • Immunohistochemical staining of paraffin embedded human tonsil with purified ab157210 at a working dilution of 1/2500. The secondary antibody used is ab97051, a goat anti-rabbit IgG (H&L) at a dilution of 1/500. The sample is counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.
    • Immunofluorescent analysis of Jurkat cells labeling MHC Class II with unpurified ab157210 at 1/50 dilution.

    • Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labeling MHC Class II with unpurified ab157210 at 1/100 dilution.

    • All lanes : Anti-HLA-DPB1 antibody [EPR11226] (ab157210) at 1/20000 dilution (purified)

      Lane 1 : Human fetal thymus lysate
      Lane 2 : Human tonsil lysate
      Lane 3 : Human fetal spleen lysate

      Lysates/proteins at 20 µg per lane.

      Secondary
      All lanes : Anti-rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

      Predicted band size: 29 kDa
      Observed band size: 29 kDa



      Blocking buffer: 5% NFDM/TBST
      Dilution buffer: 5% NFDM/TBST

    • ab157210 (purified) at 1/70 immunoprecipitating MHC Class II in 10 μg Daudi cell lysate (Lanes 1 and 2, observed at 29 kDa). Lane 3 - Rabbit monoclonal IgG (ab172730). For western blotting, HRP Veriblot for IP (ab131366) was used as the secondary antibody (1/1000). Blocking buffer and concentration: 5% NFDM/TBST Dilution buffer and concentration: 5% NFDM/TBST
    • Immunofluorescence staining of Raji cells with purified ab157210 at a working dilution of 1/250, counter-stained with DAPI. The secondary antibody was Alexa Fluor® 488 goat anti-rabbit (ab150077), used at a dilution of 1/1000. ab7291, a mouse anti-tubulin antibody (1/1000), was used to stain tubulin along with ab150120 (Alexa Fluor® 594 goat anti-mouse, 1/1000), shown in the top right hand panel. The cells were fixed in 100% methanol and permeabilized using 0.1% Triton X 100. The negative controls are shown in bottom middle and right hand panels - for negative control 1, purified ab157210 was used at a dilution of 1/500 followed by an Alexa Fluor® 594 goat anti-mouse antibody (ab150120) at a dilution of 1/500. For negative control 2, ab7291 (mouse anti-tubulin) was used at a dilution of 1/500 followed by an Alexa Fluor® 488 goat anti-rabbit antibody (ab150077) at a dilution of 1/400.

    • Immunohistochemical staining of paraffin embedded human skeletal muscle with purified ab157210 at a working dilution of 1/2500. The secondary antibody used is ab97051, a goat anti-rabbit IgG (H&L) at a dilution of 1/500. The sample is counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.
    • Unpurified ab157210 showing positiveve staining in human normal colon.

    • Unpurified ab157210 showing negative staining in Human heart.

    • Unpurified ab157210 showing negative staining in Human normal brain.

    • All lanes : Anti-HLA-DPB1 antibody [EPR11226] (ab157210) at 1/10000 dilution (Unpurified)

      Lane 1 : Human fetal thymus cell lysate
      Lane 2 : Human tonsil cell lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 29 kDa

    • Anti-HLA-DPB1 antibody [EPR11226] (ab157210) at 1/10000 dilution (Unpurified) + Immunoprecipitation pellet from Human fetal thymus lysate at 10 µg

      Predicted band size: 29 kDa

    References

    This product has been referenced in:
    • Hong D  et al. Human-induced pluripotent stem cell-derived macrophages and their immunological function in response to tuberculosis infection. Stem Cell Res Ther 9:49 (2018). WB . Read more (PubMed: 29482598) »
    • Han S  et al. LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4. J Exp Clin Cancer Res 36:83 (2017). Read more (PubMed: 28641579) »

    See all 3 Publications for this product

    Customer reviews and Q&As

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Sample
    Human Tissue sections (Liver)
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: pH9 95°C 60'
    Permeabilization
    Yes - TX-100 20'
    Specification
    Liver
    Blocking step
    Non-Serum Protein BLock as blocking agent for 20 minute(s) · Concentration: 100% · Temperature: RT°C
    Fixative
    10% NBF
    Username

    Research Technician. Alex D

    Verified customer

    Submitted May 22 2018

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up